Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | PDE6A | P16499 | 2/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 9/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946042 | 0.87 | FYN (0.47) | FYNF2RL3PIK3CGTP53MAPT | |
| SCHEMBL1945978 | 0.83 | FYN (0.47) | FYNF2RL3TP53MAPTSMN1; SMN2 | |
| SCHEMBL1946389 | 0.83 | FYN (0.68) | FYNF2RL3MAPT | |
| SCHEMBL1943656 | 0.82 | FYN (0.50) | FYNF2RL3TP53 | |
| SCHEMBL1944720 | 0.81 | FYN (0.48) | FYNPDE5APDE6AF2RL3MAPT | |
| SCHEMBL2253417 | 0.81 | FYN (0.54) | FYNF2RL3TP53SMN1; SMN2 | |
| SCHEMBL1945061 | 0.81 | MKNK1 (0.44) | FYNPDE5AF2RL3TP53MAPT | |
| SCHEMBL1946123 | 0.81 | CD274 (0.55) | FYNPDE5APDE6AMAPT | |
| SCHEMBL1946444 | 0.80 | FYN (0.53) | FYNF2RL3TP53MAPT | |
| SCHEMBL1943151 | 0.80 | FYN (0.67) | FYNF2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885PDE5A 1490/4885PDE6A 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.